Study on PK of Hydronidone in Patients and Special Population
Status:
Completed
Trial end date:
2021-01-30
Target enrollment:
Participant gender:
Summary
1. Evaluate the pharmacokinetic (PK) characteristics of Hydronidone capsule in target
patients (patients with chronic viral hepatitis b with liver fibrosis) and special
population (patients with mild liver dysfunction).
2. To evaluate the effect of oral Hydronidone capsule on QT/QTc in patients with chronic
viral hepatitis b accompanied by hepatic fibrosis and mild hepatic dysfunction.